Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
10.31
-0.18 (-1.76%)
Mar 20, 2026, 1:11 PM EDT - Market open
Valneva SE Employees
Valneva SE had 700 employees as of June 30, 2025.
Employees
700
Change
n/a
Growth
n/a
Revenue / Employee
$292,959
Profits / Employee
-$193,214
Market Cap
893.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 700 | - | - |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Xeris Biopharma Holdings | 435 |
| UroGen Pharma | 291 |
| uniQure | 221 |
| Inhibrx Biosciences | 161 |
| CytomX Therapeutics | 121 |
| GH Research | 73 |
| Compass Therapeutics | 39 |
VALN News
- 1 day ago - Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - GuruFocus
- 1 day ago - Full Year 2025 Valneva SE Earnings Call Transcript - GuruFocus
- 2 days ago - Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology - GuruFocus
- 2 days ago - Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 2 days ago - Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program - PRNewsWire
- 2 days ago - Earnings Scheduled For March 18, 2026 - Benzinga
- 2 days ago - Valneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today - Nasdaq
- 2 days ago - Valneva (VALN) Reports 3% Revenue Growth, Projects Lower 2026 Sales - GuruFocus